Close Menu

NEW YORK –  PerkinElmer said this week that it expects to report year-over-year third quarter revenue growth of 35 percent on a reported basis, and revenues growth of 33 percent on an organic basis. The Waltham, Massachusetts-based firm said the uptick was driven by continued better-than-expected demand for its SARS-CoV-2 testing products as demand for RT-PCR, RNA extraction systems and kits, and automated liquid handling instruments remained "robust." SARS-CoV-2-related products contributed about $280 million to revenues during the third quarter, PerkinElmer said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.